AIGEN Sciences Raises 12B KRW in Funding   

by Kay Aloha Villamor in October 21st, 2024

AIGEN Sciences, a Seoul, South Korea-based AI-driven new drug development company, has raised 12 billion KRW in funding. 

Investors 

Existing investors Partners Investment, Quad Asset Management, and Medytox Venture Investment, along with new investors Premier Partners, K2 Investment, and Scaleup Partners, participated in the round. 

AIGEN Sciences Use of Funds 

The company will use the funding to enhance its drug development capabilities and accelerate growth. 

About AIGEN Sciences 

Founded in April 2021, AIGEN Sciences is an AI drug discovery platform that provides drug research and development services. It utilizes its proprietary AI drug development platform to create small-molecule synthetic drugs targeting intractable diseases with high unmet medical needs. Its robust pipeline includes multiple lead substance optimizations and preclinical candidates. The company aims to advance state-of-the-art AI drug discovery technologies and transform high-cost, low-efficiency drug discovery practices into rapid, efficient processes. 

Funding Details 

Company: AIGEN Sciences, Inc. 

Raised: 12.0B KRW 

Round: Unknown 

Funding Date: October 2024 

Investors: Partners Investment, Quad Asset Management, Medytox Venture Investment, Premier Partners, K2 Investment, Scaleup Partners 

Company Website: https://www.aigensciences.com/  

Software Category: AI Drug Development 

Source: https://wowtale.net/2024/10/16/231237/ 

Your cart